 |
13 Diseases |  |
0 Trials |
|
0 Trials |  |
224 News |  |
| «123 |
- |||||||||| rapastinel (GLYX-13) / AbbVie
New P3 trial: A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) (clinicaltrials.gov) - Oct 13, 2016
P3, N=700, Not yet recruiting, Sponsor: Allergan
- ||| rapastinel (GLYX-13) / AbbVie
Enrollment change: Open Label Extension for GLYX13-C-202, NCT01684163 (clinicaltrials.gov) - Feb 22, 2016
P2, N=61, Active, not recruiting, Sponsor: Naurex, Inc
N=100 --> 61
- rapastinel (GLYX-13) / AbbVie
Trial completion, Enrollment change, Trial primary completion date: Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder (clinicaltrials.gov) - Feb 10, 2016
P2, N=8, Completed, Sponsor: New York State Psychiatric Institute
N=100 --> 61 Recruiting --> Completed | N=20 --> 8 | Trial primary completion date: Dec 2016 --> Feb 2016
- rapastinel (GLYX-13) / AbbVie
Trial completion, Enrollment change, Trial primary completion date: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - Jan 27, 2016
P2, N=104, Completed, Sponsor: Northwestern University
Recruiting --> Completed | N=20 --> 8 | Trial primary completion date: Dec 2016 --> Feb 2016 Recruiting --> Completed | N=48 --> 104 | Trial primary completion date: Aug 2017 --> Jan 2016
- ||| rapastinel (GLYX-13) / AbbVie
Trial completion, Enrollment change: Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers (clinicaltrials.gov) - Jan 27, 2016
P1, N=53, Completed, Sponsor: Naurex, Inc
Recruiting --> Completed | N=48 --> 104 | Trial primary completion date: Aug 2017 --> Jan 2016 Active, not recruiting --> Completed | N=20 --> 53
- rapastinel (GLYX-13) / AbbVie
Trial primary completion date: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - Oct 6, 2015
P2, N=48, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | N=20 --> 53 Trial primary completion date: Aug 2015 --> Aug 2017
- ||| rapastinel (GLYX-13) / AbbVie
Enrollment closed: Open Label Extension for GLYX13-C-202, NCT01684163 (clinicaltrials.gov) - Jul 21, 2015
P2, N=100, Active, not recruiting, Sponsor: Naurex, Inc
Trial primary completion date: Aug 2015 --> Aug 2017 Not yet recruiting --> Active, not recruiting
- rapastinel (GLYX-13) / AbbVie
Enrollment closed: Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers (clinicaltrials.gov) - Jul 20, 2015
P1, N=20, Active, not recruiting, Sponsor: Naurex, Inc
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- rapastinel (GLYX-13) / AbbVie
Trial primary completion date: Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers (clinicaltrials.gov) - Jun 11, 2015
P1, N=20, Recruiting, Sponsor: Naurex, Inc
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Oct 2015
- rapastinel (GLYX-13) / AbbVie
Enrollment change: Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder (clinicaltrials.gov) - Apr 16, 2015
P2, N=20, Recruiting, Sponsor: New York State Psychiatric Institute
Trial primary completion date: Dec 2014 --> Oct 2015 N=45 --> 20
- ||| rapastinel (GLYX-13) / AbbVie
Trial initiation date: Open Label Extension for GLYX13-C-202, NCT01684163 (clinicaltrials.gov) - Jan 22, 2015
P2, N=100, Not yet recruiting, Sponsor: Naurex, Inc
N=45 --> 20 Initiation date: Aug 2014 --> Feb 2015
- |||| rapastinel (GLYX-13) / AbbVie
Trial completion, Enrollment change, Trial primary completion date: Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants (clinicaltrials.gov) - Jan 22, 2015
P2, N=371, Completed, Sponsor: Naurex, Inc
Initiation date: Aug 2014 --> Feb 2015 Active, not recruiting --> Completed | N=300 --> 371 | Trial primary completion date: Mar 2014 --> Jun 2014
- rapastinel (GLYX-13) / AbbVie
Trial primary completion date: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - Dec 9, 2014
P2, N=48, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | N=300 --> 371 | Trial primary completion date: Mar 2014 --> Jun 2014 Trial primary completion date: Dec 2014 --> Aug 2015
- rapastinel (GLYX-13) / AbbVie
New P2 trial: Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder (clinicaltrials.gov) - Oct 17, 2014
P2, N=45, Recruiting, Sponsor: New York State Psychiatric Institute
- ||||| rapastinel (GLYX-13) / AbbVie
New P2 trial: Open Label Extension for GLYX13-C-202, NCT01684163 (clinicaltrials.gov) - Jul 16, 2014
P2, N=100, Not yet recruiting, Sponsor: Naurex, Inc
- rapastinel (GLYX-13) / AbbVie
Trial primary completion date: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - May 21, 2014
P2, N=48, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: Nov 2014 --> Dec 2014
- rapastinel (GLYX-13) / AbbVie
Trial completion date: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - May 21, 2014
P2, N=48, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Nov 2014 --> Dec 2014 Trial completion date: Dec 2014 --> Feb 2015
- ||| rapastinel (GLYX-13) / AbbVie
Enrollment closed: Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants (clinicaltrials.gov) - Feb 17, 2014
P2, N=300, Active, not recruiting, Sponsor: Naurex, Inc
Trial completion date: Dec 2014 --> Feb 2015 Recruiting --> Active, not recruiting
- rapastinel (GLYX-13) / AbbVie
Enrollment open: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - May 22, 2013
P2, N=48, Recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- rapastinel (GLYX-13) / AbbVie
New P2 trial: Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness (clinicaltrials.gov) - Apr 29, 2013
P2, N=48, Recruiting, Sponsor: Northwestern University
- ||||| rapastinel (GLYX-13) / AbbVie
New P2 trial: Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants (clinicaltrials.gov) - Sep 10, 2012
P2, N=300, Active, not recruiting, Sponsor: Naurex, Inc
- ||| rapastinel (GLYX-13) / AbbVie
Enrollment change: Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression (clinicaltrials.gov) - Sep 9, 2012
P2, N=115, Completed, Sponsor: Naurex, Inc
Not yet recruiting --> Recruiting N=80 --> 115
- |||| rapastinel (GLYX-13) / AbbVie
Trial completion: Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression (clinicaltrials.gov) - Sep 9, 2012
P2, N=115, Completed, Sponsor: Naurex, Inc
N=80 --> 115 Recruiting --> Completed